Events Calendar

January 9-12, 2023

41st Annual JP Morgan Health Care Conference

San Francisco, CA

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer; Mr. Scott Beck, MBA, Vyriad Chief Operating Officer; Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer; and Luke Russell, Ph.D., Vyriad Director of Business Development and Strategic Alliances will be attending the 41st Annual JP Morgan Health Care Conference.

Read more

December 7-9, 2022

ESMO Immuno-Oncology Congress

Geneva, Switzerland

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer will be attending the 2022 ESMO Immuno-Oncology Congress

Read more

December 10-13, 2022

American Society of Hematology Annual Meeting

Virtual

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer will be attending the ASH Annual Meeting virtually.

Read more

December 6-8, 2022

7th Oncolytic Virotherapy Summit

Boston, MA

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer.  Presentation: “Intravenous Administration of an Oncolytic Vesicular Stomatitis Virus: Clinical Experience to Date.”

Sheryl Tran, Vyriad Senior Director, Quality and Compliance.  Presentation:  Workshop A – Advancing CMC, Quality Control & Manufacturing Policies

Read more

October 23-26, 2022

14th International Oncolytic Virotherapy Conference

Nagano, Japan

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer will be attending the 14th International Oncolytic Virotherapy Conference

Read more

June 13-16, 2022

BIO International Convention

San Diego, CA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, and Luke Russell, Ph.D., Vyriad Director of Alliance Management will be attending the BIO International Convention in San Diego.

Read more

June 3-7, 2022

American Society of Clinical Oncology Annual Meeting (ASCO)

Chicago, IL

Luke Russell, Ph.D., Vyriad Director of Alliance Management and Alice Bexon, M.D., Vyriad Chief Medical Officer. Poster Presentation:  Jose Lutzky, M.D., University of Miami Health System. VV1 oncolytic virus + cemiplimab + Ipilimumab in patients with melanoma or NSCLC

Read more

May 15-19, 2022

American Society of Gene & Cell Therapy 25th Annual Meeting (ASGCT)

Washington, DC

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, attending the ASGCT Annual Meeting virtually.

Read more

January 10-13, 2022

40th Annual JP Morgan Health Care Conference


Virtual

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, and Luke Russell, Ph.D., Vyriad Director of Alliance Management attended the virtual 40th Annual JP Morgan Health Care Conference

Read more

November 10-14, 2021

The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC)

Washington, DC

Dr. Alice Bexon, Vyriad, Chief Medical Officer; Vino Raj, Vyriad, Medical Director; and Rebecca Thomason, Vyriad, Clinical Program Manager, will be attending the 36th SITC meeting in Washington, DC

Read more

November 5-7, 2021

International Oncolytic Virus Conference (IOVC)

Sedona, AZ / virtual meeting

Dr. Kah Whye Peng was presented with the Golden Virus Award for her outstanding contribution to the field of virotherapy.

Read more

October 7-10, 2021

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer

Virtual Meeting

Dr. Shruthi Naik, Vyriad, Vice President, Comparative Oncology.  Poster presentation:  Safety and efficacy of neoadjuvant intravesical MV-NIS in patients with urothelial carcinoma

Read more

October 5-6, 2021

Cambridge Health Institute’s (CHI) 6th Annual Oncolytic Virus Immunotherapy Summit

Virtual

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Resurgence of the Oncolytic Measles Platform: Armed, Resurfaced and Precision Targeted.”

Read more

September 9-10, 2021

The 27th Annual Meeting of the Japan Society of Gene and Cell Therapy (JSGCT)

Tokyo, Japan

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Intravenous Oncolytic Virotherapy Using Voyager-V1 (VSV-IFNb-NIS).”

Read more

June 8-10, 2021

2021 Antibody Engineering and Therapeutics Europe Meeting

Virtual

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Lentiviral Vectors Stealthed for In Vivo T Cell Transduction and Retargeted Via Surface Display of a CD3-Specific scFv.”

Read more

June 1, 2021

Medlab Middle East – Genetics Focus Day, Dubai

Virtual

Dr. Rianna Vandergaast, Principal Scientist for Imanis Life Sciences. Presentation: “IMMUNO-COV: Measuring Protection From SARS-CoV-2.”

Read more

May 19-21, 2021

7th Annual World Medical Innovation Forum

Virtual

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Entrepreneurial Growth / Oncolytic Virus.” Panel Discussion: “Entrepreneurial Snapshot / Growing Capability Company by Company”

Read more

May 11-14, 2021

American Society of Gene & Cell Therapy 24th Annual Meeting (ASGCT) Virtual

Stephen J. Russell, M.D., Ph.D., President of ASGCT and Vyriad Chief Executive Officer presented the “Welcome Statement”.

Dr. Russell held the “Fireside Chat” with Jennifer A. Doudna, Ph.D., co-recipient of the 2020 Nobel Prize in Chemistry for the discovery of the genome-editing tool CRISPR-Cas9.

Dr. Russell chaired the following Roundtable Discussion:
“COVID-19: Vaccines to the Rescue” with Sarah Gilbert, Ph.D., University of Oxford; Larry Corey, M.D., Fred Hutchinson Cancer Research Center; Gregory Poland, M.D., Mayo Clinic; Ligia Pinto, Ph.D., Frederick National Laboratory for Cancer Research and Philip Dormitzer, M.D., Ph.D., Pfizer

Read more

October 26, 2020

Career Path Workshop at Sanford Research

Sioux Falls, SD

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer. Presentation: “Career Paths in Industry.”

Read more

October 6-8, 2020

Cambridge Health Institute’s (CHI) 5th Annual Oncolytic Virus Immunotherapy Summit

Virtual

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Engineering the Immune Response to Blaze a Trail for Oncolytic Immunotherapy.” Panel Discussion: Current Challenges in Oncolytic Virotherapy

Read more

May 29-June 2 2020

American Society of Clinical Oncology

Virtual

Poster Presentations:
Ph 2 trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma

Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy

Read more

May 12-15, 2020

American Society of Gene & Cell Therapy 23rd Annual Meeting (ASGCT)

Virtual

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: Education Talk with Overview “Choosing the OV Platform: Considerations”

Read more

December 3-5, 2019

Oncolytic Virotherapy Summit

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Pharmico-Dynamic Non-Invasive Monitoring Techniques”

See Speakers

Read more

October 28-31, 2019

World Vaccine Congress Europe 2019

Barcelona, Spain

Shruthi Naik, Ph.D., Vyriad Vice President of Comparative Oncology
Presentation: “Unlocking the Potential of Oncolytic Viruses to Target Cancer Cells”

Read more

October 9-12, 2019

International Oncolytic Virus 12th Annual Conference

Rochester, MN

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Opening Remarks

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Inflaming tumors with systemic VSV therapy”

Read more

August 8, 2019

Cambridge Healthtech Institutes (CHI) 2nd Annual Immuno-Oncology Investing & Partnering Forum

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Novel Therapeutics and Diagnostics for Cancer Immunotherapy”

Read more

August 6-7, 2019

Cambridge Health Institute’s (CHI) 4th Annual Oncolytic Virus Immunotherapy Summit

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic OV Therapy Using Voyager-V1”

Read more

July 21-23, 2019

The 25th Annual Meeting of Japan Society of Gene and Cell Therapy and The International Gene & Cell Therapy Symposium

Tokyo, Japan

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Intravenous Virotherapy: Inflaming Tumors via the Blood Stream”

Read more

April 10-11, 2019

Cambridge Healthtech Institute’s Inaugural Oncolytic Viral Therapy Conference: Engineering, Translational and Clinical Strategies

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Antibody Targeted Viruses: The Next Generation of Oncolytics”

Read more

March 18-22, 2019

Immuno-Oncology Summit Europe

London, UK

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus”

Read more

March 11-13, 2019

Cambridge Healthtech Institute’s 4th Annual Cancer Immunotherapy: Executive Summit

San Francisco, CA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Voyager-V1: Systemic, Single-cycle, Trackable Oncolytic Virotherapy”

Read more

February 11-12, 2019

Bio CEO and Investor Conference

New York, NY

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Presentation: “Oncolytic Viruses for IV Cancer Therapy”

Read more

January 7-10, 2019

37th Annual JP Morgan Healthcare Conference

San Francisco, CA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 37th Annual JP Morgan Healthcare Conference in San Francisco.

Read more

December 4-6, 2018

4th Oncolytic Virotherapy Summit

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus.”
Dr. Russell will also co-chair a panel session entitled: Comparing and Contrasting Virus Types.

Read more

November 27-29, 2018

30th Annual Piper Jaffray Healthcare Conference

New York, NY

Stephen J. Russell, M.D., Ph.D., Vyriad President and CEO, attended the 30th Annual Piper Jaffray Healthcare Conference in New York.

Read more

August 27-28, 2018

Cambridge Healthtech Institute’s 3rd Annual Oncolytic Virus Immunotherapy: Commercializing the Exciting Potential of Oncolytic Virotherapy

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Progress with Oncolytic Vesicular Stomatitis Viruses”

Read more

June 26-28, 2018

Armed Oncolytic Immunotherapies Summit

Frankfurt, Germany

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform”
Dr. Russell will participate in a panel discussion, “Explore Novel Approaches to Identify the Most Rational Combinations“

Read more

June 1-5, 2018

American Society of Clinical Oncology (ASCO) Annual Meeting

Chicago, Illinois

Alice Bexon, M.D., Vyriad Chief Medical Officer will attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Read more

May 16-19, 2018

18th Annual American Society of Cell & Gene Therapy (ASGCT) meeting

Chicago, IL

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been elected Vice-President of ASGCT. ASGCT has elected four new members to the Board of Directors, including Dr. Stephen J. Russell as new incoming vice president. Dr. Russell will serve a yearlong term as vice president before serving as ASGCT’s president-elect and, finally, president through the 2021 annual meeting. Dr. Russell will be Co-Chairing: Clinical Trials Spotlight I at the annual meeting. Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to present: Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging and Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging

Read more

April 9-12, 2018

International Oncolytic Virus Conference

Oxford, UK

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to Chair, Innate and collateral adaptive tumor immunity. Dr. Russell will also participate in Steve Russell (Once should be enough!) vs. Alan Melcher (Repeat dosing is crucial!) Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to Chair, Translation, imaging and clinical breakthroughs. Dr. Peng will be presenting: Oncolytic virus encoding IFNbeta: optimizing therapeutic index.

Read more

January 8-11, 2018

36th Annual JP Morgan Healthcare Conference

San Francisco, CA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 36th Annual JP Morgan Healthcare Conference in San Francisco.

Read more

December 5-7, 2017

Oncolytic Virotherapy Summit

Miami, Florida

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, was invited as a panel member for: How Can We Improve the Efficacy of Oncolytic Virotherapies? Dr. Russell also provided a presentation entitled “VSV-IFNb-NIS and MV-NIS: A Tale of Two Paradigms” and managed a workshop entitled “Optimizing Oncolytic Viruses: Identifying the Right Viral Platform”

Read more

November 28-29, 2017

29th Annual Piper Jaffray Healthcare Conference

New York, New York

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presented “Oncolytic Virotherapy: The Next Major Breakthrough in Cancer Treatment” at the 28th Annual Piper Jaffray Healthcare Conference

Read more

November 8-12, 2017

The 32nd Annual Society for Immunotherapy of Cancer (SITC) meeting

National Harbor, Maryland

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, attended the annual SITC meeting

Read more

November 4, 2017

Dr. Boenjamin Setiawan Distinguished Lectureship for 2017

Jakarta, Indonesia

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Invited to present “Oncolytic Viruses: An Emerging Cornerstone for Immuno-oncology” at the Dr. Boenjamin Setiawan Distinguished Lecture Series

Read more

February 23-25, 2017

ASCO-SITC Clinical Immuno-Oncology Symposium

Orlando, Florida

Stephen J Russell from Vyriad was invited to present on “Viral Therapy” at the ASCO-SITC conference on exploiting viruses for cancer therapy in combination with immune modulators.

Read more

October 1-4, 2016

The 10th International Meeting on Replicating Oncolytic Virus Therapeutics

Vancouver, Canada

Kah-Whye Peng, PhD, CTO of Vyriad gave a Plenary presentation entitled “Vesicular stomatitis virus (VSV) as an oncolytic agent”. Stephen J. Russell, MD, PhD, CEO & President of Vyriad gave a Plenary presentation entitled “Measles as a versatile oncolytic agent”.

Read more

June 18, 2016

35th Annual Meeting of the American Society of Virology

Blacksburg, VA

Keynote Lecture: “Oncolytic Viruses: Past, Present, and Future” Stephen J. Russell, MD, PhD, CEO & President, Vyriad.

Read more